Wells Fargo Maintains Overweight on Biomarin Pharmaceutical, Raises Price Target to $110
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has maintained an Overweight rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and raised the price target from $100 to $110.
April 25, 2024 | 2:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo has maintained an Overweight rating on Biomarin Pharmaceutical and increased the price target from $100 to $110.
The upgrade in the price target by a reputable analyst like Mohit Bansal from Wells Fargo is a strong positive signal for Biomarin Pharmaceutical. It suggests confidence in the company's future performance and growth prospects, likely leading to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100